Insight into pharmaceutical deals and trends

Generics Bulletin

Sun Finds US ‘Challenging’

By Penelope MacRae 17 Feb 2020

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Topic Deal trends

Generics Bulletin

Coherus Is Confident After US Ranibizumab Filing

By Aidan Fry 27 Jan 2020

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deal trends

Scrip

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

By Jung Won Shin 15 Jan 2020

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

Topic Clinical Trials Deal trends

Generics Bulletin

Biocon Biologics Gets True North Investment

By Anju Ghangurde 08 Jan 2020

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic Deal trends Strategy

Scrip

Novartis Sees Reimbursement Advantage For PCSK9 Launch

By Jessica Merrill 28 Nov 2019

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

Topic Business Strategies Deal trends Reimbursement

Medtech Insight

Recipharm Boosts Inhalation And Injectables Manufacturing By Acquiring UK's Consort Medical

By Marion Webb 20 Nov 2019

Sweden's Recipharm has agreed to buy UK-based Consort Medical for £505m ($652m) to become a leading inhalation-device company and top five global CDMO.

Topic Deal trends

Generics Bulletin

Lupin Offloads Kyowa For $525m But Not Exiting Japan

By Vibha Ravi 13 Nov 2019

Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

Topic Deal trends Strategy